Following the long weekend, two Chinese IPOs and a preclinical biotch are currently scheduled to list in the US in the week ahead: China’s largest LGBTQ dating app BlueCity (BLCT), on-demand worker platform Quhuo (QH), and preclinical oncology biotech Nkarta (NKTX)
More deals could join the IPO calendar, based on a flurry of filing activity in June, including health insurance marketplace GoHealth (GHTH), cloud banking software provider nCino (NCNO), workers’ comp insurer Trean Insurance (TIG), and several biotechs (IVA, INM) and SPACs.
BlueCity Holdings (BLCT) plans to raise $85 million at a $614 million market cap. The company provides a full suite of LGBTQ-focused services including live streaming, memberships, and advertising, among others. Central to the company’s business is the Blued mobile app, had over 49 million registered users on Blued as of March 31, 2020, and its average MAUs grew from 4.1 million in the 1Q18 to 6.0 million in the 1Q20.
Quhuo (QH) plans to raise $27 million at a $450 million market cap. China’s largest workforce operational solution platform, Quhuo has a presence in 73 cities across 26 provinces, and its customers include large enterprises like Meituan, KFC, Mobike, and Didi.
Nkarta (NKTX) plans to raise $150 million at a $426 million market cap. The company’s co-lead candidate, NKX101, is designed to enhance the power of innate natural killer biology to detect and kill cancerous cells. The company submitted an IND for NKX101 for the treatment of relapsed or refractory acute myeloid leukemia and higher-risk myelodysplastic syndromes in May 2020, and it plans to initiate a broad clinical program for blood cancers and solid tumors this year.
Several micro-caps recently set terms for their IPOs and may flip the switch at some point in July. These include preclinical biotech Kiromic BioPharma (KRBP), late-stage biotech Greenwich LifeSciences (GLSI), diversified REIT Presidio Property Trust (SQFT), real estate developer Harbor Custom Development (HCDI), and e-commerce platform 1847 Goedeker (GOED).
|U.S. IPO Calendar|
|BlueCity Holdings (BLCT)
|$15 – $17
Loop Capital Markets
|Leading online LGBTQ community and dating platform in China.|
South San Francisco, CA
|$14 – $16
|Preclinical developer of off-the-shelf cancer therapies based on natural killer cells.|
|$9 – $11
|Provides workforce operations solutions for consumer service platforms in China.|
Sign up for a free trial of our premium platform, IPO Pro. Follow us on Twitter (@IPOtweet) and register for our updates on the IPO market.
This past week, Renaissance Capital released its 2Q20 US IPO Market Review, which provides in-depth analysis of IPO activity, highlighting the quarter’s largest deals, most active sectors, best-performing IPOs, and more.
Street research is expected for eight companies. Screen for Street research dates and lock-up period expirations by signing up for a free trial of IPO Pro.
IPO Market Snapshot
The Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 7/1/20, the Renaissance IPO Index was up 31.5% year-to-date, while the S&P 500 was down 3.6%. Renaissance Capital’s IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Zoom Video (ZM) and Uber (UBER). The Renaissance International IPO Index was up 16.8% year-to-date, while the ACWX was down 10.4%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Meituan-Dianping and Xiaomi.
The article US IPO Week Ahead: Third quarter kicks off with China’s largest gay dating app originally appeared on IPO investment manager Renaissance Capital’s web site renaissancecapital.com.
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital’s research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital’s Renaissance IPO ETF (symbol: IPO), Renaissance International ETF (symbol: IPOS), or separately managed institutional accounts may have investments in securities of companies mentioned.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.